The cutting-edge eLLi surgical device, which has been crafted to address severe pathology associated with EOS, signals a notable shift in technology used to extend growing rods in pediatric patients. Faced with a condition that can potentially be life-threatening due to the likelihood of thoracic insufficiency, these patients require effective and safe methods of orthopedic assistance.
The eLLi Surgical device stands out due to its non-invasive approach. The goal of the eLLi system is to deliver an advanced and reliable system of extending growing rods with increased force, superior distraction precision, and enhanced mechanical reliability that are unmatched by current technologies. Importantly, this would address the outstanding safety concerns associated with other technology in use.
What sets eLLi apart from existing technologies is that it offers surgeons a new alternative to address spinal deformities in growing children. The optimizer of growth for the child can be maintained, ensuring a safer and more comfortable future for these young patients.
Speaking on the breakthrough, a representative from OrthoPediatrics Corp. said, eLLi will allow surgeons a new alternative to address deformity of the growing spine with an advanced technology that will complement our efforts to build a platform of EOS technologies. He further expressed the company’s pride in the expert design team, comprising surgeons who have devoted their careers to the treatment of these unique patients.
The company receiving the Breakthrough Device Designation from the FDA does not only position OrthoPediatrics Corp at the forefront of pediatric orthopedics but also buoy the ongoing efforts in innovating ways to combat the challenges associated with EOS. The innovative eLLi technology promises less invasive and more effective treatment options for pediatric patients with scoliosis, creating a brighter future for those affected by this condition.
Comments